Search

Your search keyword '"Yamaguchi, Shigeru"' showing total 981 results
Start Over Author "Yamaguchi, Shigeru"
981 results on '"Yamaguchi, Shigeru"'

6. TERT promoter mutation confers favorable prognosis regardless of 1p/19q status in adult diffuse gliomas with IDH1/2 mutations.

Author

Arita, Hideyuki, Matsushita, Yuko, Machida, Ryunosuke, Yamasaki, Kai, Hata, Nobuhiro, Ohno, Makoto, Yamaguchi, Shigeru, Sasayama, Takashi, Tanaka, Shota, Higuchi, Fumi, Iuchi, Toshihiko, Saito, Kuniaki, Kanamori, Masayuki, Matsuda, Ken-Ichiro, Miyake, Yohei, Tamura, Kaoru, Tamai, Sho, Nakamura, Taishi, Uda, Takehiro, Okita, Yoshiko, Fukai, Junya, Sakamoto, Daisuke, Hattori, Yasuhiko, Pareira, Eriel, Hatae, Ryusuke, Ishi, Yukitomo, Miyakita, Yasuji, Tanaka, Kazuhiro, Takayanagi, Shunsaku, Otani, Ryohei, Sakaida, Tsukasa, Kobayashi, Keiichi, Saito, Ryuta, Kurozumi, Kazuhiko, Shofuda, Tomoko, Nonaka, Masahiro, Suzuki, Hiroyoshi, Shibuya, Makoto, Komori, Takashi, Sasaki, Hikaru, Mizoguchi, Masahiro, Kishima, Haruhiko, Nakada, Mitsutoshi, Sonoda, Yukihiko, Tominaga, Teiji, Nagane, Motoo, Nishikawa, Ryo, Kanemura, Yonehiro, Kuchiba, Aya, Narita, Yoshitaka, and Ichimura, Koichi

Subjects
1p/19q codeletion, CDKN2A, Glioma, IDH1/2, TERT, Adolescent, Adult, Aged, Aged, 80 and over, Astrocytoma, Brain Neoplasms, Chromosome Deletion, Chromosomes, Human, Pair 1, Chromosomes, Human, Pair 19, Female, Glioblastoma, Glioma, Humans, Isocitrate Dehydrogenase, Karnofsky Performance Status, Male, Middle Aged, Multivariate Analysis, Mutation, Neoplasm Grading, Neurosurgical Procedures, Oligodendroglioma, Prognosis, Promoter Regions, Genetic, Proportional Hazards Models, Radiotherapy, Adjuvant, Retrospective Studies, Survival Rate, Telomerase, Young Adult
Abstract

TERT promoter mutations are commonly associated with 1p/19q codeletion in IDH-mutated gliomas. However, whether these mutations have an impact on patient survival independent of 1p/19q codeletion is unknown. In this study, we investigated the impact of TERT promoter mutations on survival in IDH-mutated glioma cases. Detailed clinical information and molecular status data were collected for a cohort of 560 adult patients with IDH-mutated gliomas. Among these patients, 279 had both TERT promoter mutation and 1p/19q codeletion, while 30 had either TERT promoter mutation (n = 24) or 1p/19q codeletion (n = 6) alone. A univariable Cox proportional hazard analysis for survival using clinical and genetic factors indicated that a Karnofsky performance status score (KPS) of 90 or 100, WHO grade II or III, TERT promoter mutation, 1p/19q codeletion, radiation therapy, and extent of resection (90-100%) were associated with favorable prognosis (p

Published
2020

9. A common deletion at BAK1 reduces enhancer activity and confers risk of intracranial germ cell tumors

Author

Sonehara, Kyuto, Kimura, Yui, Nakano, Yoshiko, Ozawa, Tatsuya, Takahashi, Meiko, Suzuki, Ken, Fujii, Takashi, Matsushita, Yuko, Tomiyama, Arata, Kishikawa, Toshihiro, Yamamoto, Kenichi, Naito, Tatsuhiko, Suzuki, Tomonari, Yamaguchi, Shigeru, Miwa, Tomoru, Sasaki, Hikaru, Kitagawa, Masashi, Ohe, Naoyuki, Fukai, Junya, Ogiwara, Hideki, Kawamura, Atsufumi, Miyawaki, Satoru, Matsuda, Fumihiko, Kiyokawa, Nobutaka, Ichimura, Koichi, Nishikawa, Ryo, Okada, Yukinori, and Terashima, Keita

Published
2022
Full Text
View/download PDF

10. Efficacy and safety of nivolumab in Japanese patients with first recurrence of glioblastoma: an open-label, non-comparative study

Author

Aoki, Tomokazu, Kagawa, Naoki, Sugiyama, Kazuhiko, Wakabayashi, Toshihiko, Arakawa, Yoshiki, Yamaguchi, Shigeru, Tanaka, Shota, Ishikawa, Eiichi, Muragaki, Yoshihiro, Nagane, Motoo, Nakada, Mitsutoshi, Suehiro, Satoshi, Hata, Nobuhiro, Kuroda, Junichiro, Narita, Yoshitaka, Sonoda, Yukihiko, Iwadate, Yasuo, Natsumeda, Manabu, Nakazato, Yoichi, Minami, Hironobu, Hirata, Yuki, Hagihara, Shunsuke, and Nishikawa, Ryo

Published
2021
Full Text
View/download PDF

12. Identifying G6PC3 as a Potential Key Molecule in Hypoxic Glucose Metabolism of Glioblastoma Derived from the Depiction of 18F-Fluoromisonidazole and 18F-Fluorodeoxyglucose Positron Emission Tomography

Author

Okamoto, Michinari, primary, Yamaguchi, Shigeru, additional, Sawaya, Ryosuke, additional, Echizenya, Sumire, additional, Ishi, Yukitomo, additional, Kaneko, Sadahiro, additional, Motegi, Hiroaki, additional, Toyonaga, Takuya, additional, Hirata, Kenji, additional, and Fujimura, Miki, additional

Published
2024
Full Text
View/download PDF

17. Observation of notable therapeutic response in a patient with systemic juvenile xanthogranuloma with KIF5B-ALK fusion

Author

Sugiyama, Minako, primary, Hirabayashi, Shinsuke, additional, Ishi, Yukitomo, additional, Kikuchi, Junko, additional, Ishikura, Ayako, additional, Motegi, Hiroaki, additional, Ueda, Yuki, additional, Sawai, Saori, additional, Hara, Kazuya, additional, Terashita, Yukayo, additional, Cho, Yuko, additional, Takakuwa, Emi, additional, Honda, Shohei, additional, Yamaguchi, Shigeru, additional, Kinoshita, Ichiro, additional, and Manabe, Atsushi, additional

Published
2024
Full Text
View/download PDF

18. 10007-ACT-2 FIRST IN HUMAN STUDY OF DSP-0390, AN ORAL EMOPAMIL BINDING PROTEIN (EBP) INHIBITOR, IN RECURRENT HIGH-GRADE GLIOMA (HGG): PRELIMINARY RESULTS

Author

Arakawa, Yoshiki, primary, Goldlust, Samuel A, additional, Colman, Howard, additional, Reardon, David A, additional, Welch, Mary R, additional, Yamaguchi, Shigeru, additional, Butowski, Nicholas A, additional, Li, Jian, additional, Iino, Shuichi, additional, Song, Gregory, additional, Jackman, Aimee, additional, Xie, Yuran, additional, Wagle, Marie-Claire, additional, Lebedinsky, Claudia, additional, and Narita, Yoshitaka, additional

Published
2023
Full Text
View/download PDF

19. CTNI-72. PHASE II TRIAL OF PATHOLOGY-BASED THREE-GROUP TREATMENT STRATIFICATION FOR PATIENTS WITH CNS GERM CELL TUMORS: A LONG-TERM FOLLOW-UP STUDY

Author

Fulvio D'Angelo, Hirokazu Takami, primary, Suzuki, Tomonari, additional, Takabatake, Kazuhiko, additional, Fujimaki, Takamitsu, additional, Okamoto, Michinari, additional, Yamaguchi, Shigeru, additional, Kanamori, Masayuki, additional, Matsuda, Kenichiro, additional, Sonoda, Yukihiko, additional, Natsumeda, Manabu, additional, Ichinose, Junya, additional, Nakada, Mitsutoshi, additional, Muroi, Ai, additional, Ishikawa, Eiichi, additional, Takahashi, Masamichi, additional, Narita, Yoshitaka, additional, Higuchi, Fumi, additional, Shin, Masahiro, additional, Mineharu, Yohei, additional, Arakawa, Yoshiki, additional, Kagawa, Naoki, additional, Kawabata, Shinji, additional, Wanibuchi, Masahiko, additional, Takayasu, Takeshi, additional, Yamasaki, Fumiyuki, additional, Fujii, Kentaro, additional, Ishida, Joji, additional, Date, Isao, additional, Miyake, Keisuke, additional, Fujioka, Hiroshi, additional, Kuga, Daisuke, additional, Yamashita, Shinji, additional, Takeshima, Hideo, additional, Shinojima, Naoki, additional, Mukasa, Akitake, additional, Tanaka, Shota, additional, Asai, Akio, additional, Nishikawa, Ryo, additional, and Matsutani, Masao, additional

Published
2023
Full Text
View/download PDF

20. CTNI-67. FIRST IN HUMAN STUDY OF DSP-0390, AN ORAL EMOPAMIL BINDING PROTEIN (EBP) INHIBITOR, IN RECURRENT HIGH-GRADE GLIOMA (HGG): PRELIMINARY RESULTS

Author

Arakawa, Yoshiki, primary, Goldlust, Samuel, additional, Colman, Howard, additional, Reardon, David, additional, Welch, Mary, additional, Yamaguchi, Shigeru, additional, Butowski, Nicholas, additional, Li, Jian, additional, Iino, Shuichi, additional, Song, Gregory, additional, Jackman, Aimee, additional, Xie, Yuran, additional, Wagle, Marie-Claire, additional, Lebedinsky, Claudia, additional, and Narita, Yoshitaka, additional

Published
2023
Full Text
View/download PDF

26. Identifying G6PC3 as a Potential Key Molecule in Hypoxic Glucose Metabolism of Glioblastoma Derived from the Depiction of 18F-Fluoromisonidazole and 18F-Fluorodeoxyglucose Positron Emission Tomography.

Author

Okamoto, Michinari, Yamaguchi, Shigeru, Sawaya, Ryosuke, Echizenya, Sumire, Ishi, Yukitomo, Kaneko, Sadahiro, Motegi, Hiroaki, Toyonaga, Takuya, Hirata, Kenji, and Fujimura, Miki

Subjects
*GLUCOSE metabolism, *STAINS & staining (Microscopy), *GENETIC mutation, *GLIOMAS, *PHOSPHATASES, *METABOLISM, *IMIDAZOLES, *CANCER patients, *QUALITATIVE research, *COMPARATIVE studies, *RADIOPHARMACEUTICALS, *POSITRON emission tomography, *GENE expression profiling, *FLUORESCENT antibody technique, *MESSENGER RNA, *DESCRIPTIVE statistics, *RESEARCH funding, *CEREBRAL anoxia, *DEOXY sugars, *CELL lines, *TUMOR markers, *OVERALL survival, *MEDICAL logic
Abstract

Purpose. Glioblastoma is the most aggressive primary brain tumor, characterized by its distinctive intratumoral hypoxia. Sequential preoperative examinations using fluorine-18-fluoromisonidazole (18F-FMISO) and fluorine-18-fluorodeoxyglucose (18F-FDG) positron emission tomography (PET) could depict the degree of glucose metabolism with hypoxic condition. However, molecular mechanism of glucose metabolism under hypoxia in glioblastoma has been unclear. The aim of this study was to identify the key molecules of hypoxic glucose metabolism. Methods. Using surgically obtained specimens, gene expressions associated with glucose metabolism were analyzed in patients with glioblastoma (n = 33) who underwent preoperative 18F-FMISO and 18F-FDG PET to identify affected molecules according to hypoxic condition. Tumor in vivo metabolic activities were semiquantitatively evaluated by lesion-normal tissue ratio (LNR). Protein expression was confirmed by immunofluorescence staining. To evaluate prognostic value, relationship between gene expression and overall survival was explored in another independent nonoverlapping clinical cohort (n = 17) and validated by The Cancer Genome Atlas (TCGA) database (n = 167). Results. Among the genes involving glucose metabolic pathway, mRNA expression of glucose-6-phosphatase 3 (G6PC3) correlated with 18F-FDG LNR (P = 0.03). In addition, G6PC3 mRNA expression in 18F-FMISO high-accumulated glioblastomas was significantly higher than that in 18F-FMISO low-accumulated glioblastomas (P < 0.01). Protein expression of G6PC3 was consistent with mRNA expression, which was confirmed by immunofluorescence analysis. These findings indicated that the G6PC3 expression might be facilitated by hypoxic condition in glioblastomas. Next, we investigated the clinical relevance of G6PC3 in terms of prognosis. Among the glioblastoma patients who received gross total resection, mRNA expressions of G6PC3 in the patients with poor prognosis (less than 1-year survival) were significantly higher than that in the patients who survive more than 3 years. Moreover, high mRNA expression of G6PC3 was associated with poor overall survival in glioblastoma, as validated by TCGA database. Conclusion. G6PC3 was affluently expressed in glioblastoma tissues with coincidentally high 18F-FDG and 18F-FMISO accumulation. Further, it might work as a prognostic biomarker of glioblastoma. Therefore, G6PC3 is a potential key molecule of glucose metabolism under hypoxia in glioblastoma. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

27. Slow-growing WNT medulloblastoma with atypical magnetic resonance imaging findings: illustrative case

Author

Mizushima, Makoto, primary, Okamoto, Michinari, additional, Yamaguchi, Shigeru, additional, Oki, Sogo, additional, Motegi, Hiroaki, additional, Sugiyama, Minako, additional, Manabe, Atsushi, additional, Shimizu, Ai, additional, Nishioka, Kentaro, additional, Hashimoto, Takayuki, additional, Hirato, Junko, additional, Kanemura, Yonehiro, additional, and Fujimura, Miki, additional

Published
2023
Full Text
View/download PDF

31. Identifying G6PC3 as a potential key molecule in hypoxic glucose metabolism of glioblastoma derived from the depiction of 18F-fluoromisonidazole and 18F-fluorodeoxyglucose positron emission tomography

Author

Okamoto, Michinari, primary, Yamaguchi, Shigeru, additional, Sawaya, Ryosuke, additional, Echizenya, Sumire, additional, Ishi, Yukitomo, additional, Kaneko, Sadahiro, additional, Motegi, Hiroaki, additional, Toyonaga, Takuya, additional, Hirata, Kenji, additional, and Fujimura, Miki, additional

Published
2023
Full Text
View/download PDF

32. Supratentorial multifocal gliomas associated with Ollier disease harboringIDH1 R132Hmutation: A case report

Author

Ikeda, Hiroshi, primary, Yamaguchi, Shigeru, additional, Ishi, Yukitomo, additional, Wakabayashi, Kento, additional, Shimizu, Ai, additional, Kanno‐Okada, Hiromi, additional, Endo, Takeshi, additional, Ota, Mitsutoshi, additional, Okamoto, Michinari, additional, Motegi, Hiroaki, additional, Iwasaki, Norimasa, additional, and Fujimura, Miki, additional

Published
2023
Full Text
View/download PDF

33. The need of radiotherapy optimization for glioblastomas considering immune responses

Author

1000080463743, Nishioka, Kentaro, Takahashi, Shuhei, Mori, Takashi, Uchinami, Yusuke, Yamaguchi, Shigeru, Kinoshita, Manabu, Yamashina, Masaaki, Higaki, Hajime, Maebayashi, Katsuya, 1000080360915, Aoyama, Hidefumi, 1000080463743, Nishioka, Kentaro, Takahashi, Shuhei, Mori, Takashi, Uchinami, Yusuke, Yamaguchi, Shigeru, Kinoshita, Manabu, Yamashina, Masaaki, Higaki, Hajime, Maebayashi, Katsuya, 1000080360915, and Aoyama, Hidefumi

Abstract

Glioblastoma is the most common of malignant primary brain tumors and one of the tumors with the poorest prognosis for which the overall survival rate has not significantly improved despite recent advances in treatment techniques and therapeutic drugs. Since the emergence of immune checkpoint inhibitors, the immune response to tumors has attracted increasing attention. Treatments affecting the immune system have been attempted for various tumors, including glioblastomas, but little has been shown to be effective. It has been found that the reason for this is that glioblastomas have a high ability to evade attacks from the immune system, and that the lymphocyte depletion associated with treatment can reduce its immune function. Currently, research to elucidate the resistance of glioblastomas to the immune system and development of new immunotherapies are being vigorously carried out. Targeting of radiation therapy for glioblastomas varies among guidelines and clinical trials. Based on early reports, target definitions with wide margins are common, but there are also reports that narrowing the margins does not make a significant difference in treatment outcome. It has also been suggested that a large number of lymphocytes in the blood are irradiated by the irradiation treatment to a wide area in a large number of fractionations, which may reduce the immune function, and the blood is being recognized as an organ at risk. Recently, a randomized phase II trial comparing two types of target definition in radiotherapy for glioblastomas was conducted, and it was reported that the overall survival and progression-free survival were significantly better in a small irradiation field group. We review recent findings on the immune response and the immunotherapy to glioblastomas and the novel role of radiotherapy and propose the need to develop an optimal radiotherapy that takes radiation effects on the immune function into account.

Published
2023

34. Uniformity evaluation of laser-induced periodic surface structures formed by two-color double-pulse femtosecond laser irradiation

Author

TAKENAKA, Keisuke, HASHIDA, Masaki, SAKAGAMI, Hitoshi, MASUNO, Shin-ichiro, KUSABA, Mitsuhiro, YAMAGUCHI, Shigeru, IWAMORI, Satoru, SATO, Yuji, TSUKAMOTO, Masahiro, TAKENAKA, Keisuke, HASHIDA, Masaki, SAKAGAMI, Hitoshi, MASUNO, Shin-ichiro, KUSABA, Mitsuhiro, YAMAGUCHI, Shigeru, IWAMORI, Satoru, SATO, Yuji, and TSUKAMOTO, Masahiro

Abstract

The Perpendicular Period and Phase Scanning (P3S) method can evaluate the uniformity of a laser-induced periodic surface structure (LIPSS). P3S assesses the uniformity of LIPSS using the standard deviation of the peak period and the average of the phase difference in the direction perpendicular to LIPSS. The P3S method demonstrates that LIPSS formed by two-color double-pulse irradiation is reduced to a quarter of the period dispersion, and the average phase difference of LIPSS is also reduced compared to the single-pulse irradiation. In addition, a 3D electromagnetic particle-in-cell simulation was performed to evaluate the possibility of an improved uniformity of LIPSS. The results confirm that the two-color double-pulse irradiation produces a uniform LIPSS and validates the effectiveness of the P3S method to assess the uniformity of LIPSS., source:Review of Scientific Instruments 93, 093001 (2022); https://doi.org/10.1063/5.0096218, source:https://doi.org/10.1063/5.0096218, identifier:0000-0003-4461-0081

Published
2023

37. Cystic Intracranial Recurrence of Olfactory Neuroblastoma without Accumulation on Fluorine-18-fluorodeoxyglucose Positron Emission Tomography

Author

Ishi, Yukitomo, Yamaguchi, Shigeru, Hatanaka, Kanako C., Takakuwa, Emi, Motegi, Hiroaki, Honda, Taishi, Kobayashi, Hiroyuki, Terasaka, Shunsuke, Homma, Akihiro, Fujimura, Miki, and Houkin, Kiyohiro

Subjects
olfactory neuroblastoma, intracranial recurrence, esthesioneuroblastoma, fluorine-18-fluorodeoxyglucose positron emission tomography, cystic recurrence
Abstract

A 66-year-old man underwent multimodal treatment for olfactory neuroblastoma (ONB). When he was 72 years old, a cystic intracranial lesion without accumulation on fluorine-18-fluorodeoxyglucose positron emission tomography was detected. Surgical resection was performed when the patient was 73 years old. The pathological examination revealed recurrence of ONB, and the patient underwent focal irradiation. At age 81, he presented with a second recurrence in the right occipital lobe with radiological and pathological findings similar to the prior recurrence. This case suggests that pathological confirmation should be considered in cases with atypical radiological findings following the treatment of ONB.

Published
2022

38. Molecular field analysis in half-titanocene complexes: computational study towards data-driven in silicooptimization of single-site olefin polymerization catalystsElectronic supplementary information (ESI) available. See DOI: https://doi.org/10.1039/d4cy00241e

Author

Yamaguchi, Shigeru, Kikuchi, Takahiro, Tanaka, Kenichi, and Takamiya, Ikuko

Abstract

We performed molecular field analysis using computed data of half-titanocene-catalyzed olefin polymerization. The activation energies of ethylene insertion, propylene insertion, and the energy differences between ethylene insertion and β-hydrogen transfer calculated with DFT methods were employed as target variables for regression analysis. Molecular fields (voxel data) calculated from corresponding transition-state structures were used as descriptors. The structural information visualized based on the molecular field-based regression analysis provided a catalyst design guideline. A phosphinimide catalyst designed following the guideline showed enhanced computed free energy values. According to a previous report, the designed catalyst exhibited higher activity and polymer molecular weight in ethylene polymerization compared to a high performance phosphinimide catalyst in the training samples.

Published
2024
Full Text
View/download PDF

39. Supratentorial multifocal gliomas associated with Ollier disease harboring IDH1 R132H mutation: A case report.

Author

Ikeda, Hiroshi, Yamaguchi, Shigeru, Ishi, Yukitomo, Wakabayashi, Kento, Shimizu, Ai, Kanno‐Okada, Hiromi, Endo, Takeshi, Ota, Mitsutoshi, Okamoto, Michinari, Motegi, Hiroaki, Iwasaki, Norimasa, and Fujimura, Miki

Subjects
*FRONTAL lobe, *FLUORESCENCE in situ hybridization, *GLIOMAS, *ISOCITRATE dehydrogenase, *MAGNETIC resonance imaging
Abstract

Somatic mosaicism of isocitrate dehydrogenase 1/2 (IDH1/2) mutation is a cause of Ollier disease (OD), characterized by multiple enchondromatosis. A 35‐year‐old woman who was diagnosed with OD at age 24 underwent resection surgery for multifocal tumors located at the right and left frontal lobes that were discovered incidentally. No apparent spatial connection was observed on preoperative magnetic resonance imaging. Pathological examinations revealed tumor cells with a perinuclear halo in the left frontal lobe tumor, whereas astrocytic tumor cells were observed in the right frontal lobe tumor. Based on positive IDH1 R132H immunostaining and the result of 1p/19q fluorescent in situ hybridization, pathological diagnoses were IDH mutant and 1p/19q‐codeleted oligodendroglioma in the right frontal lobe tumor and IDH mutant astrocytoma in the left frontal lobe tumor, respectively. The DNA sequencing revealed IDH1 R132H mutation in the peripheral blood sample and frontal lobe tumors. This case suggested that in patients with OD, astrocytoma and oligodendroglioma can co‐occur within the same individual simultaneously, and IDH1 R132H mutation was associated with supratentorial development of gliomas. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

40. Safety and efficacy of tumour-treating fields (TTFields) therapy for newly diagnosed glioblastoma in Japanese patients using the Novo-TTF System: a prospective post-approval study

Author

Nishikawa, Ryo, primary, Yamasaki, Fumiyuki, additional, Arakawa, Yoshiki, additional, Muragaki, Yoshihiro, additional, Narita, Yoshitaka, additional, Tanaka, Shota, additional, Yamaguchi, Shigeru, additional, Mukasa, Akitake, additional, and Kanamori, Masayuki, additional

Published
2023
Full Text
View/download PDF

44. BOT-3 GENOME-WIDE ASSOCIATION STUDY OF INTRACRANIAL GERM CELL TUMORS: A COMMON DELETION ATBAK1 ATTENUATES THE ENHANCER ACTIVITY AND CONFERS RISK FOR THE BRAIN TUMORS IN CHILDREN ADOLESCENTS AND YOUNG ADULTS

Author

Terashima, Keita, primary, Sonehara, Kyuto, additional, Kimura, Yui, additional, Nakano, Yoshiko, additional, Ozawa, Tatsuya, additional, Takahashi, Meiko, additional, Suzuki, Ken, additional, Fujii, Takashi, additional, Matsushita, Yuko, additional, Tomiyama, Arata, additional, Suzuki, Tomonari, additional, Yamaguchi, Shigeru, additional, Miwa, Tomoru, additional, Sasaki, Hikaru, additional, Kitagawa, Masashi, additional, Ohe, Naoyuki, additional, Fukai, Junya, additional, Ogiwara, Hideki, additional, Kawamura, Atsufumi, additional, Miyawaki, Satoru, additional, Matsuda, Fumihiko, additional, Kiyakawa, Nobutaka, additional, Ichimura, Koichi, additional, Nishikawa, Ryo, additional, and Okada, Yukinori, additional

Published
2022
Full Text
View/download PDF

45. PEDT-10 PHASE II TRIAL OF PATHOLOGY-BASED THREE-GROUP TREATMENT STRATIFICATION FOR PATIENTS WITH CNS GERM CELL TUMORS: A LONG-TERM FOLLOW-UP STUDY

Author

Takami, Hirokazu, primary, Suzuki, Tomonari, additional, Takabatake, Kazuhiko, additional, Fujimaki, Takamitsu, additional, Okamoto, Michinari, additional, Yamaguchi, Shigeru, additional, Kanamori, Masayuki, additional, Matsuda, Kenichiro, additional, Sonoda, Yukihiko, additional, Natsumeda, Manabu, additional, Ichinose, Junya, additional, Nakada, Mitsutoshi, additional, Muroi, Ai, additional, Ishikawa, Eiichi, additional, Takahashi, Masamichi, additional, Narita, Yoshitaka, additional, Higuchi, Fumi, additional, Shin, Masahiro, additional, Mineharu, Yohei, additional, Arakawa, Yoshiki, additional, Kagawa, Naoki, additional, Kawabata, Shinji, additional, Wanibuchi, Masahiko, additional, Takayasu, Takeshi, additional, Yamasaki, Fumiyuki, additional, Fujii, Kentaro, additional, Ishida, Joji, additional, Date, Isao, additional, MIyake, Keisuke, additional, Fujioka, Hiroshi, additional, Kuga, Daisuke, additional, Yamashita, Shinji, additional, Takeshima, Hideo, additional, Shinojima, Naoki, additional, Mukasa, Akitake, additional, Tanaka, Shota, additional, Asai, Akio, additional, Nishikawa, Ryo, additional, and Matsutani, Masao, additional

Published
2022
Full Text
View/download PDF

47. Long-term consequences of residual lesions after chemoradiotherapy in patients with germinoma at onset

Author

Yamaguchi, Shigeru, primary, Okamoto, Michinari, additional, Ishi, Yukitomo, additional, Sawaya, Ryosuke, additional, Motegi, Hiroaki, additional, Sugiyama, Minako, additional, Harada, Taisuke, additional, Fujima, Noriyuki, additional, Mori, Takashi, additional, Hashimoto, Takayuki, additional, Takakuwa, Emi, additional, Manabe, Atsushi, additional, Kudo, Kohsuke, additional, Aoyama, Hidefumi, additional, and Fujimura, Miki, additional

Published
2022
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results